Lobbying client
CABALETTA BIO
Clinical-stage biotechnology company focused on T cell therapies
Filings
5
Filed by
1
Reported in-house
—
Reported by firms
$50,000
Filings
5 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
4th Quarter - Termination (No Activity) 4th Quarter 2025
|
HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) | — reported |
|
3rd Quarter - Report (No Activity) 3rd Quarter 2025
|
HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) | — reported |
|
2nd Quarter - Report 2nd Quarter 2025
|
HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) | $20,000 reported |
|
1st Quarter - Report 1st Quarter 2025
|
HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) | $30,000 reported |
|
Registration 1st Quarter 2025
|
HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP) | 4 | $50,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Medicare/Medicaid | MMM | 3 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.